TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial (Q83532323)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22374408%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

title

TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22374408%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1 reference

phase II clinical trial

1 reference

inferred from title

type 2 diabetes

0 references

placebo-controlled trial

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22374408%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

author name string

Prabhakar Viswanathan

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22374408%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

John Marcinak

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22374408%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Charlie Cao

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22374408%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Majid Vakilynejad

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22374408%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Benhuai Xie

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22374408%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Eckhard Leifke

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22374408%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

language of work or name

English

0 references

publication date

27 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22374408%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

number of pages

9

1 reference

inferred from page(s)

published in

The Lancet

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22374408%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

volume

379

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22374408%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

issue

9824

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22374408%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

page(s)

1403-1411

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22374408%20AND%20SRC:MED&resulttype=core&format=json

Impact of GPCRs in clinical medicine: monogenic diseases, genetic variants and drug targets

24 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961879-5

7 January 2021

The G protein-coupled receptor repertoires of human and mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961879-5

7 January 2021

Modulation of osteoclastogenesis by fatty acids

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961879-5

7 January 2021

Oleic acid induces intracellular calcium mobilization, MAPK phosphorylation, superoxide production and granule release in bovine neutrophils.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961879-5

7 January 2021

Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961879-5

7 January 2021

The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961879-5

7 January 2021

Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961879-5

7 January 2021

Conjugated linoleic acids mediate insulin release through islet G protein-coupled receptor FFA1/GPR40.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961879-5

7 January 2021

Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961879-5

7 January 2021

Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961879-5

7 January 2021

Epac: A new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961879-5

7 January 2021

GPR40: good cop, bad cop?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961879-5

7 January 2021

Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961879-5

7 January 2021

The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961879-5

7 January 2021

Glimepiride pharmacokinetics in obese versus non-obese diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961879-5

7 January 2021

Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961879-5

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961879-5

7 January 2021

IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961879-5

7 January 2021

Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961879-5

7 January 2021

Management of type 2 diabetes: new and future developments in treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961879-5

7 January 2021

10.1016/S0140-6736(11)61879-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22374408%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1 reference